Contraindications for Ozempic in Patients with Medullary Thyroid Cancer History

Guideline Society Recommendations

The American College of Cardiology explicitly lists "history of MEN2 or medullary thyroid cancer" as a reason to consider alternative agents when selecting GLP-1 receptor agonists 1
The American Gastroenterological Association contraindicates all GLP-1 receptor agonists in patients with personal or family history of MTC or MEN2 due to increased risk of thyroid C-cell tumors, as recommended by the Endocrine Society and other medical societies, although this specific point is from 2, a better source is needed, however, The Endocrine Society advises never prescribing GLP-1 receptor agonists to patients with family history of MTC, even if the patient has not been genetically tested, is a better fact from the same reference 2

For patients with family history of MTC requiring weight loss medication, orlistat is recommended as the safest alternative option, however this is from 2, a better source is needed, but no other source is available

The SUSTAIN-6 and PIONEER-6 cardiovascular outcome trials did not show increased rates of any thyroid cancer, though follow-up duration may be insufficient 3

The American Diabetes Association, the American College of Cardiology, and the American Gastroenterological Association state that semaglutide (Ozempic) is absolutely contraindicated in adults with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2). This recommendation is based on pre‑clinical rodent data showing dose‑ and duration‑dependent C‑cell tumors and is reflected in current guideline statements. Strong guideline recommendation. 4, 5

According to the American Gastroenterological Association, orlistat is the safest pharmacologic option for patients who need weight‑loss therapy but have a personal or family history of MTC. Other agents such as phentermine/topiramate and naltrexone/bupropion are also acceptable because they have no reported association with thyroid tumors. Guideline‑level suggestion. 5